Skip to content
Screener

MiMedx Group MDXG Q3 2025 earnings

Reported October 29, 2025 · After market close

Revenue$113.7MBeat by $6.8M
EPS$0.15Beat by $0.08
Revenue estimate$106.9M
EPS estimate$0.07

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$69.6M
EPS estimate$0.01

Financials

Q3 2025

Income statement

See full
Revenue$113.7M+35.3%
Gross profit$95.0M+38.2%
Operating income$22.2M+98.8%
Net income$16.7M+107%
EPS (diluted)$0.11+120%

Balance sheet

See full
Cash & equivalents$142.1M+60.0%
Total debt$18.2M-4.2%
Total equity$238.9M+32.0%
Total assets$319.0M+30.8%

Cash flow

See full
Operating cash flow$29.3M+49.5%
CapEx$192.0K+12.3%
Free cash flow$29.1M+49.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.03B+19.0%
Enterprise value$908.89M+13.9%
P/E25.3×+15.5×
P/S2.6×+0.1×

Profitability

See full
Gross margin82%-1.4pp
Operating margin13.7%-8.1pp
Net margin10.4%-15.4pp
FCF margin17%+0.7pp

Returns & leverage

See full
Return on equity19.4%-77.6pp
Debt / equity0.1×0.0×
Current ratio4.4×+0.3×

Segments

By product

See full
Wound$77.1M—
Surgical$36.6M—

FAQ

When did MiMedx Group report Q3 2025 earnings?
MiMedx Group (MDXG) reported Q3 2025 earnings on October 29, 2025 after market close.
What were MiMedx Group's Q3 2025 revenue and EPS?
MiMedx Group reported revenue of $113.7M and eps of $0.15 for Q3 2025.
Did MiMedx Group beat estimates in Q3 2025?
Revenue beat the consensus estimate of $106.9M by $6.8M. EPS beat the consensus estimate of $0.07 by $0.08.
How did MiMedx Group's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 35.3% from $84.1M a year earlier and eps grew 200.0% from $0.05.
Where can I find MiMedx Group's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001376339-25-000104) and the 10-Q periodic report (0001376339-25-000103) directly on SEC EDGAR. The filing index links above go to sec.gov.